Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

TAvi6, a bispecific antibody targeting VEGF-A/ANG-2 inhibits angiogenesis in vivo

Dec. 3, 2010

Ascenta Therapeutics and Ascentage Pharma form alliance for cancer programs

Dec. 3, 2010

GenSpera adds trial site to G-202 phase I clinical program

Dec. 3, 2010

Chugai Pharma presents in vivo data on new potential cancer therapeutics

Dec. 3, 2010

Agennix discloses interim data from first-in-human trial of RGB-286638 in hematologic tumors

Dec. 3, 2010

Oncolytics Biotech begins enrollment in phase II Reolysin study in ovarian cancer

Dec. 2, 2010

FDA to request further information for Cavatak IND for phase II melanoma trial

Dec. 2, 2010

Medivation and Astellas complete enrollment in phase III MDV-3100 trial

Dec. 2, 2010

Phase I trial of INK-128 initiated in multiple myeloma

Dec. 2, 2010

Elara Pharma's new antitumor agent EL-102 inhibits HIF-1-alpha and cellular proliferation

Dec. 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...